Atmo Biosciences, a digital health company that is developing the world’s first ingestible gas-sensing capsule for monitoring gut health, has closed an oversubscribed A$9.6m capital raise.
Planet Innovation is redefining what it means to be a strategic investor by providing investee companies with not just funding, but access to its people, facilities and networks.
Lumos Diagnostics, a PI investee company, has been admitted to the Australian Securities Exchange (ASX) with trading commencing on July 5 after raising $63 million AUD in an Initial Public Offering (IPO).
Atmo Biosciences is ramping up manufacture of its third generation gas-sensing capsule at Planet Innovation’s recently opened new medtech manufacturing facility.
PI’s business model has been proven a success with another of its investee companies – Visus Therapeutics™ – raising $US36 ($A47) million in Series A financing.
Visus Therapeutics, a company backed by Planet Innovation, has started a clinical development program for a novel eye drop designed to restore the loss of near vision associated with aging.
Lumos Diagnostics, a rapid point-of-care diagnostics company spun out of Planet Innovation, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.
Atmo Biosciences has been awarded a $620,000 Australian Government grant through the BioMedTech Horizons (BMTH) program.
A roundup of the latest news and opinions from PI.
Atmo Biosciences, a digital health business that provides objective real-time insights into gut health and microbiome function, has raised a further A$2.5 million in an oversubscribed funding round, supplementing an initial seed raise in March 2019.
Planet Innovation has agreed to a $A20 million strategic investment in Lumos Diagnostics, a rapid point-of-care diagnostics company.
Seed Health, a US-based microbial sciences company, and Atmo Biosciences, a Planet Innovation early stage venture, have announced a partnership to use Atmo’s ingestible gas-sensing capsule to study the impact of probiotics on the gut microbiome.
November 18-24 is World Antibiotic Awareness Week, so it’s a good time to draw attention to the global health challenge of antibiotic resistance, which Planet Innovation is combating through its business Lumos Diagnostics.
Atmo Biosciences, a Planet Innovation early stage venture, has signed a licensing deal with RMIT University to secure the exclusive worldwide rights to a ground-breaking ingestible gas-sensing capsule.
Lumos Diagnostics is expanding its global footprint after agreeing an ongoing manufacturing deal for a customized lateral flow reader with a California-based life sciences company.
Planet Innovation has launched Vitalic Medical, a digital health venture addressing two major problems for general wards in hospitals around the world: undetected patient deterioration and in-hospital patient falls.
Lumos Diagnostics develops custom products for its partners using a unique combination of integrated assay and engineering capability paired with its proven reader optical technologies.
Zen Ecosystems has received a major grant by the Australian Renewable Energy Agency (ARENA) to help secure Australia’s energy supplies during times of peak demand.
Planet Innovation’s PoC (Point-of-Care) diagnostic platform, Nplex, will benefit from further investment to develop a cloud-connected medical counter-measures device, for the rapid detection of infectious diseases.
Zen Thermostat, a PI venture, has been selected by Telstra to be sold as part of its soon to be released Smart Home Platform.
Zen is a smart thermostat launched by Planet Innovation with a successful crowd funding campaign.